Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β
复制标题
DOI：
10.1001/jamaneurol.2019.4421
复制
发表时间：
2020-04-01
期刊：
影响因子：
29
通讯作者：
Rosa-Neto, Pedro
中科院分区：
文献类型：
--
作者：
Therriault, Joseph;Benedet, Andrea L.;Rosa-Neto, Pedro
本研究调查载脂蛋白E β 4是否与内侧颞叶tau蛋白病理学相关，与淀粉样蛋白β、性别、临床状态和年龄无关。重要性载脂蛋白E β 4（APOE β 4）是阿尔茨海默病最重要的遗传危险因素。虽然APOE β 4与淀粉样蛋白β负荷增加有关，但其与脑tau病理学的关系一直存在争议。目的确定APOE β 4是否与内侧颞叶tau蛋白病理学相关，而与淀粉样蛋白β、性别、临床状态和年龄无关。设计、设置和参与者这是一项对认知正常、轻度认知障碍（MCI）或阿尔茨海默病痴呆的2个横断面队列志愿者的研究：衰老和痴呆中的翻译生物标志物（TRIAD）研究（数据收集于2017年10月至2019年7月）和阿尔茨海默病神经影像学倡议（ADNI）（2015年11月至2019年6月期间收集）。第一个队列（TRIAD）包括认知正常的老年受试者（n = 124）、MCI受试者（n = 50）和阿尔茨海默病受试者（n = 50），这些受试者接受了使用氟18标记的MK 6240进行的tau正电子发射断层扫描（PET）和使用[F-18] AZD 4694进行的淀粉样蛋白β PET。第二个样本（ADNI）由认知正常的老年受试者（n = 157）、MCI受试者（n = 83）和阿尔茨海默病受试者（n = 25）组成，这些受试者接受了含[F-18] flortaucipir的tau PET和含[F-18] florbetapir的淀粉样蛋白-β PET。排除标准是有其他神经系统疾病、中风或头部创伤史。有489名合格的参与者，根据淀粉样蛋白PET，tau-PET，磁共振成像和APOE β 4基因分型的可用性进行选择。45岁的年轻人（
This study investigates whether apolipoprotein E epsilon 4 is associated with medial temporal tau pathology independently of amyloid-beta, sex, clinical status, and age.Importance Apolipoprotein E epsilon 4 (APOE epsilon 4) is the single most important genetic risk factor for Alzheimer disease. While APOE epsilon 4 is associated with increased amyloid-beta burden, its association with cerebral tau pathology has been controversial. Objective To determine whether APOE epsilon 4 is associated with medial temporal tau pathology independently of amyloid-beta, sex, clinical status, and age. Design, Setting, and Participants This is a study of 2 cross-sectional cohorts of volunteers who were cognitively normal, had mild cognitive impairment (MCI), or had Alzheimer disease dementia: the Translational Biomarkers in Aging and Dementia (TRIAD) study (data collected between October 2017 and July 2019) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (collected between November 2015 and June 2019). The first cohort (TRIAD) comprised cognitively normal elderly participants (n = 124), participants with MCI (n = 50), and participants with Alzheimer disease (n = 50) who underwent tau positron emission tomography (PET) with fluorine 18-labeled MK6240 and amyloid-beta PET with [F-18]AZD4694. The second sample (ADNI) was composed of cognitively normal elderly participants (n = 157), participants with MCI (n = 83), and participants with Alzheimer disease (n = 25) who underwent tau PET with [F-18]flortaucipir and amyloid-beta PET with [F-18]florbetapir. Exclusion criteria were a history of other neurological disorders, stroke, or head trauma. There were 489 eligible participants, selected based on availability of amyloid-PET, tau-PET, magnetic resonance imaging, and genotyping for APOE epsilon 4. Forty-five young adults (